Oral Cannabidiol Does Not Reduce Acute Non-traumatic Low Back Pain .
The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain
Med J Aust. 2021 May;214(8): 370-375.One hundred patients with acute, non-traumatic low back pain presenting to the emergency department were randomized to receive a single-dose of oral cannabidiol (400mg) or placebo in addition to standard emergency department analgesic medication. The primary outcome of interest was pain score two hours after administration of the study agent on a verbal numerical pain scale. Secondary outcomes included length of stay, need for rescue analgesia and adverse events. There was no significant differences in mean pain scores found between the two groups. The median length of stay, need for rescue medication and reported side effects were similar between the two groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
